Back
Liberty Latin America 10K Form
Sell
17
LILAK
Liberty Latin America
Last Price:
$5.36
Seasonality Move:
-2.44%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2023-11-09 | 10Q | LILAK/Liberty Latin America Quarterly |
2023-08-08 | 10Q | LILAK/Liberty Latin America Quarterly |
2023-05-08 | 10Q | LILAK/Liberty Latin America Quarterly |
2022-11-08 | 10Q | LILAK/Liberty Latin America Quarterly |
2022-08-03 | 10Q | LILAK/Liberty Latin America Quarterly |
2022-05-04 | 10Q | LILAK/Liberty Latin America Quarterly |
Receive LILAK News And Ratings
See the #1 stock for the next 7 days that we like better than LILAK
LILAK Financial Statistics
Sales & Book Value
Annual Sales: | $4.5B |
---|---|
Cash Flow: | $234.9M |
Price / Cash Flow: | 4.95 |
Annual Sales: | $5.70 |
Price / Book: | 0.95 |
Profitability
EPS (TTM): | -3.34250 |
---|---|
Net Income (TTM): | $-657M |
Gross Margin: | $3B |
Return on Equity: | -32.29% |
Return on Assets: | -5.01% |
Liberty Latin America Earnings Forecast
Key Liberty Latin America Financial Ratios
-
The Gross Profit Margin over the past 12 years for LILAK is 66.48%.
-
The Selling, General & Administrative Expenses for LILAK have been equal to 19.13% of Gross Profit Margin.
-
The Net Earning history of LILAK is -14.74% of Total Revenues.
-
Per Share Earnings over the last 12 years have been positive in 7 years.
Liberty Latin America Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Diversified Telecommunication Services |
Sector: | Communication Services |
Current Symbol: | LILAK |
CUSIP: | G9001E |
Website: | lla.com |
Debt
Debt-to-Equity Ratio: | 7.21 |
---|---|
Current Ratio: | 1.04 |
Quick Ratio: | 0.77 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 14.67 |
LILAK Technical Analysis vs Fundamental Analysis
Sell
17
Liberty Latin America (LILAK)
is a Sell
Is Liberty Latin America a Buy or a Sell?
-
Liberty Latin America stock is rated a SellThe current Liberty Latin America [LILAK] share price is $5.39. The Score for LILAK is 17, which is 66% below its historic median score of 50, and infers higher risk than normal.